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ABSTRACT
Infants born to HIV-1-infected mothers in resource-limited areas where replacement feeding is unsafe and impractical are re-
peatedly exposed to HIV-1 throughout breastfeeding. Despite this, the majority of infants do not contract HIV-1 postnatally,
even in the absence of maternal antiretroviral therapy. This suggests that immune factors in breast milk of HIV-1-infected moth-
ers help to limit vertical transmission. We compared the HIV-1 envelope-specific breast milk and plasma antibody responses of
clade C HIV-1-infected postnatally transmitting and nontransmitting mothers in the control arm of the Malawi-based Breast-
feeding Antiretrovirals and Nutrition Study using multivariable logistic regression modeling. We found no association between
milk or plasma neutralization activity, antibody-dependent cell-mediated cytotoxicity, or HIV-1 envelope-specific IgG responses
and postnatal transmission risk. While the envelope-specific breast milk and plasma IgA responses also did not reach signifi-
cance in predicting postnatal transmission risk in the primary model after correction for multiple comparisons, subsequent ex-
ploratory analysis using two distinct assay methodologies demonstrated that the magnitudes of breast milk total and secretory
IgA responses against a consensus HIV-1 envelope gp140 (B.con env03) were associated with reduced postnatal transmission
risk. These results suggest a protective role for mucosal HIV-1 envelope-specific IgA responses in the context of postnatal virus
transmission. This finding supports further investigations into the mechanisms by which mucosal IgA reduces risk of HIV-1
transmission via breast milk and into immune interventions aimed at enhancing this response.
IMPORTANCE
Infants born to HIV-1-infected mothers are repeatedly exposed to the virus in breast milk. Remarkably, the transmission rate is
low, suggesting that immune factors in the breast milk of HIV-1-infected mothers help to limit transmission. We compared the
antibody responses in plasma and breast milk of HIV-1-transmitting and -nontransmitting mothers to identify responses that
correlated with reduced risk of postnatal HIV-1 transmission. We found that neither plasma nor breast milk IgG antibody re-
sponses were associated with risk of HIV-1 transmission. In contrast, the magnitudes of the breast milk IgA and secretory IgA
responses against HIV-1 envelope proteins were associated with reduced risk of postnatal HIV-1 transmission. The results of
this study support further investigations of the mechanisms by which mucosal IgA may reduce the risk of HIV-1 transmission
via breastfeeding and the development of strategies to enhance milk envelope-specific IgA responses to reduce mother-to-child
HIV transmission and promote an HIV-free generation.
Recent estimates indicate that breastfeeding accounts for half ofthe 260,000 pediatric HIV-1 infections that occur annually
(1). The risk of postnatal HIV-1 transmission can be significantly
decreased with maternal antiretroviral prophylaxis or by replace-
ment feeding; however, these strategies are often not viable in
resource-limited areas (2).
Remarkably, despite chronic mucosal virus exposure, the ma-
jority of breastfed infants born to HIV-1-infected mothers do not
contract HIV-1 postnatally (3, 4). The high concentration of an-
tibodies (Abs) in breast milk gives reason to suspect that adaptive
humoral immune responses are involved in natural infant protec-
tion from HIV-1 infection (5). Antibodies in milk are either trans-
ferred from the plasma by transudation or locally produced by
plasma cells that have migrated to the mammary gland from other
mucosal sites, in particular, the gut-associated lymphoid tissues
(6). Secretory IgA (SIgA) is the predominant milk immunoglob-
ulin, followed by IgM and IgG (7). HIV envelope (Env)-specific
antibodies of all three isotypes have been identified in breast milk,
but surprisingly HIV-1 Env-specific IgG responses are higher in
magnitude than HIV-1 Env-specific IgA responses and mediate
the majority of the neutralization and antibody-dependent cell-
mediated cytotoxicity (ADCC) activity found in breast milk (8–
11). However, previous studies have reported no differences in the
frequencies of detectable HIV-1 Env-specific antibody responses
between transmitting and nontransmitting mothers (9, 11–13).
These findings may point to the importance of milk antibody
specificity and/or function in infant protection.
This study aimed to determine if there is an association be-
tween the specificity and/or function of breast milk HIV Env-
specific IgG and IgA antibody responses and the risk of postnatal
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mother-to-child HIV-1 transmission. Specifically, we sought to
determine if the antibody responses associated with reduced in-
fection risk in the RV144 clinical trial, including V1/V2-specific
antibodies, V3-specific antibodies, and ADCC activity, also im-
pact postnatal HIV-1 transmission (14–19). Understanding natu-
rally elicited protective antibody responses could provide insight
into future maternal or pediatric vaccine design strategies.
MATERIALS AND METHODS
Study cohort. Breast milk and plasma samples were obtained from the
control arm of the Breastfeeding, Antiretrovirals, and Nutrition (BAN)
study (ClinicalTrials.gov number NCT00164736). This study enrolled an-
tiretroviral-naive, HIV-1-infected pregnant women in Malawi with
CD4 T cell counts above 200 cells/l (250 cells/l after 24 July 24 2006)
from 2004 to 2009. All mothers and infants in the control arm received
single-dose nevirapine at onset of labor (postpartum for infants), fol-
lowed by 7 days of zidovudine/lamivudine therapy (20). Mothers who
transmitted HIV-1 to their infants during breastfeeding (n  22) were
included in the current study and matched in a near 1:3 ratio with non-
transmitting mothers (n  65) for postpartum visit and the closest pe-
ripheral CD4 T cell count. Among the transmitting women, specimens
were selected from the last visit prior to infant HIV-1 diagnosis, and this
postpartum visit was used as a matching criterion for selection of speci-
mens from nontransmitting mothers. Plasma samples collected at the
same visit as the milk samples were also available from 42 of the 87 total
subjects (10 transmitters and 32 nontransmitters). Clinical characteristics
for the study cohort are included in Table 1. There were no significant
differences between transmitting and nontransmitting women in milk
HIV-1 viral load, peripheral CD4 T cell count, days postpartum for
sample collection, age, or gravida. High plasma viral load is known to be
associated with postnatal transmission risk (21), and within our cohort a
significant difference in plasma viral load was observed between transmit-
ters and nontransmitters (Table 1) (Wilcoxon test, P  0.003). Accord-
ingly, all subsequent statistical analyses were performed with correction
for plasma viral load, as well as peripheral CD4 T cell count.
Ethics statement. Ethical approval for the BAN study was obtained
from the Malawi National Health Science Research Committee and the
institutional review boards at the University of North Carolina at Chapel
Hill and the U.S. Centers for Disease Control and Prevention. All study
participants were adults and provided written informed consent.
Neutralization assays. Plasma and breast milk neutralization of
HIV-1 was measured by the ability of these samples to reduce virus infec-
tion of TZM-bl cells (NIH AIDS Reagent Program; contributed by John
Kappes and Xiaoyun Wu) as previously described (22). All milk samples
were delipidized by centrifugation at 25,000  g to reduce toxicity in
cellular assays as previously described (8). All assays were performed by
laboratory personnel blinded to the transmission status of the women’s
samples. Plasma and breast milk neutralization were measured against the
tier 1 HIV-1 clade C isolate MW965 (GenBank accession number
U08455). Breast milk samples were also tested for neutralization against
tier 1 HIV-1 clade B isolate MN (GenBank number M17449) and a tier 2
postnatally transmitted isolate, 1209BMH5 (GenBank number HM070570)
(23). Plasma was tested at a starting dilution of 1:20, and delipidized milk
was tested at a starting dilution of 1:10. The neutralization titer is reported
as the dilution at which the relative light units (RLU) were reduced by 50%
(50% inhibitory dose [ID50]) compared to the RLU in virus control wells.
Samples were also tested for neutralizing activity against a nonspecific
retrovirus (murine leukemia virus, SVA.MLV) to assess nonspecific inhi-
bition of viral infection in the presence of antiretroviral drugs. Neutral-
ization ID50 titers that were less than three times the nonspecific back-
ground observed against SVA.MLV were not included in the logistic
regression analysis.
ADCC assays. (i) ADCC activity against gp120-coated target cells
(ADCC-GTL assay). A GranToxiLux (GTL) assay was used to detect
ADCC activities of plasma and delipidized breast milk samples di-
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TABLE 1 Clinical characteristics of transmitting and nontransmitting
HIV-1-infected, non-antiretroviral therapy-treated maternal cohort
from the Breastfeeding, Antiretrovirals, and Nutrition Study, Malawi
Parameter and groupa






Breast milk VL (log10
copies/ml)b
Transmitters 3.45 2.59 4.65 0.244
Nontransmitters 3.17 2.45 3.59
Plasma VL (log10
copies/ml)
Transmitters 4.84 4.29 5.14 0.003
Nontransmitters 4.20 3.80 4.60
No. of peripheral CD4
T cells/l
Transmitters 324 293 445 0.950
Nontransmitters 327 273 446
Days postpartumd
Transmitters 48.5 28 85 0.981
Nontransmitters 44 29 84
Age (yr)
Transmitters 25.5 22 31 0.582
Nontransmitters 25 22 28
Gravida
Transmitters 3 2 4 0.779
Nontransmitters 3 2 4
a The data represent 22 transmitting and 65 nontransmitting mothers except for breast
milk VL as noted. VL, viral load.
b No target was detected in breast milk samples from 3 transmitters and 30
nontransmitters, and three additional breast milk samples from nontransmitters were
below the level of quantitation (100 copies/ml).
c Wilcoxon test. A significant difference (P  0.05) in plasma viral loads between
transmitters and nontransmitters is indicated in boldface.
d The time point represents the last visit prior to infant HIV-1 diagnosis for the
transmitting women; samples from nontransmitting women were matched by days
postpartum and CD4 T cell count.
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rected against gp120-coated target cells as described previously (24).
CEM.NKRCCR5 cells (NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH, from Alexandra Trkola [25]) were used as targets after
being coated with recombinant gp120 from HIV-1 isolate 4403BMC5,
representing a clade C postnatally transmitted virus (GenBank num-
ber HM070724) (23). Cryopreserved human peripheral blood mono-
nuclear cells (PBMC) from an HIV-seronegative donor with the
heterozygous 158F/V genotype for Fc-gamma receptor IIIa were used
as the source of effector cells (26). The plasma and breast milk samples
were tested after 5-fold serial dilutions starting at 1:50 and 1:10, re-
spectively. The maximum percent granzyme B (GzB) activity was de-
fined as the peak proportion of cells positive for proteolytically active
GzB out of the total viable target cell population. The final results are
expressed after subtraction of the background percent GzB activity
observed in wells containing effector and target cells in the absence of
plasma or breast milk. ADCC endpoint titers were determined by in-
terpolating the dilutions of plasma or breast milk that intersect the
positive cutoff (greater than the average percent GzB activity plus 3
standard deviations [SD] of 9 uninfected samples tested in parallel)
using GraphPad Prism, version 5, software (GraphPad).
(ii) ADCC against HIV-1-infected target cells (ADCC-Luc assay).
ADCC activity was determined by a luciferase (Luc)-based assay as previ-
ously described (17). CEM.NKRCCR5 cells were infected with an infectious
molecular clone (IMC) that encodes the HIV-1 subtype C Env from iso-
late 4403BMC5 in an NL4-3 isogenic backbone that contains the Renilla
luciferase reporter gene and preserves all HIV-1 open reading frames (27).
Infections were monitored by measuring luciferase activity (ViviRen Live
Cell Substrate; Promega) and the frequency of cells expressing intracellu-
lar p24. Greater than 75% of the target cells were p24 positive in each assay
conducted. Effector cells were the same cryopreserved PBMC used for
ADCC-GTL assays, and samples were tested at the same range of concen-
trations. ADCC activity (percent killing) was calculated from the change
in RLU amounts (ViviRen luciferase assay; Promega) resulting from the
loss of intact target cells in wells containing effector cells, target cells, and
plasma or breast milk samples compared to amounts in control wells
containing target cells and effector cells alone according to the following
formula: percent killing  [(number of RLU of target and effector well 
number of RLU of test well)/number of RLU of target and effector well]
100. We report both the maximum percent killing observed for each
sample and the ADCC endpoint titer, defined as the dilution of plasma or
breast milk that intersects the positive cutoff (greater than the average
percent killing activity plus 1 standard deviation of 9 uninfected samples,
each tested in two independent experiments).
BAMA. Levels of HIV-1 Env-specific IgA and IgG were determined
with a customized HIV-1 binding antibody multiplex assay (BAMA) as
previously described (15). Carboxylated fluorescent beads (Luminex Cor-
poration, Austin, TX) were covalently coupled to purified HIV-1 antigens
and subsequently incubated with patient samples in assay diluent (phos-
phate-buffered saline [PBS], 5% normal goat serum, 0.05% Tween 20, 1%
Blotto milk) at various dilutions. For IgG, the antigen panel included
biotinylated linear V3 loop peptide V3.C (KKKNNTRKSIRIGPGQTFYA
TGDIIGDIRQAHC) and proteins 4403 BMC5 gp120 (23), 1209 BMH5
gp120 (23), Con6 gp120/B (28), ConS gp140 (29), HIV-1 MN
recombinant gp41 (Immuno Diagnostics Incorporated, Woburn,
MA), gp70 B.CaseA2_V1V2/169K (30), gp70 B.CaseA_V1V2 (31),
gp70 C.1086C_V1V2 (30), and 1086C gp140 (32); for IgA, the antigen
panel included biotinylated linear peptides V3.C, C1 (KKKMQEDVISLW
DQSLKPCVKLTPLCV), and Bio-C1_104.BC (KKKMHEDIISLWDQSL
KPCVKLTPLCV) and proteins A1.con env03 gp140 (15), A244 gD-gp120
(15), B.con env03 gp140 (15), 4403 BMC5 gp120, Con6 gp120/B, ConS
gp140, gp41, gp70 B.CaseA2_V1V2/169K, gp70 B.CaseA_V1V2, gp70
C.1086C_V1V2, and 1086C gp140. Blank beads were used in all assays to
account for nonspecific binding. HIV-specific antibodies were detected
with phycoerythrin (PE)-conjugated goat anti-human IgA at 4 g/ml
(Jackson ImmunoResearch Laboratories, West Grove, PA) or PE-conju-
gated mouse anti-human IgG at 2 g/ml (Southern Biotech, Birmingham,
AL). HIV-specific SIgA was detected with mouse anti-human SIgA at 4
g/ml (Sigma-Aldrich), followed by goat anti-mouse IgG-PE (Southern
Biotech). Positive controls for SIgA binding included purified colostral
IgA and purified secretory component coupled to Luminex beads. The
beads were then washed and acquired on a Bio-Plex 200 instrument (Bio-
Rad Laboratories, Hercules, CA). The results were expressed as mean
fluorescence intensity (MFI). A panel of negative-control samples
(n  15, except for breast milk IgA, where additional negative-control
samples were included, for a total n  30) was included to determine
baseline, nonspecific levels of binding. All assays included tracking of HIV
immunoglobulin (HIVIG) standard by Levy-Jennings charts. The preset
assay criteria for sample reporting were coefficient of variation per dupli-
cate values of 20% for each sample and 100 beads counted per sample.
All samples were analyzed at the same dilution for each antigen. For breast
milk IgG samples, gp70 B.CaseA2_V1V2/169K, gp70 B.CaseA_V1V2, and
gp70 C.1086C_V1V2 antigens were measured at a 1:5 sample dilution;
Con6 gp120/B, ConS gp140, and V3.C antigens were measured at a
1:100 sample dilution; and HIV-1 MN recombinant gp41 and 1086C
gp140 antigens were measured at a 1:250 sample dilution. For plasma IgG
samples, gp70 B.CaseA2_V1V2/169K, gp70 B.CaseA_V1V2, gp70
C.1086C_V1V2, 4403 BMC5 gp120, and 1209 BMH5 antigens were mea-
sured at a 1:250 sample dilution; Con6 gp120/B, ConS gp140, and V3.C
antigens were measured at a 1:2,500 sample dilution; and HIV-1 MN
recombinant gp41 and 1086C gp140 antigens were measured at a 1:12,500
sample dilution. All breast milk IgA samples were measured at a 1:5 dilu-
tion, and all plasma IgA samples were measured at a 1:10 dilution. These
dilutions were predetermined to be within the linear range of the assay
based on testing serial dilutions of a small subset of breast milk/plasma
samples.
ELISA. Enzyme-linked immunosorbent assay (ELISA) plates (384
wells; Corning Life Sciences, Corning, NY) were coated overnight with 30
g/well of consensus clade B gp140 (B.con env03 gp140) in 0.1 M sodium
bicarbonate. The plates were then washed with washing buffer (phos-
phate-buffered saline [PBS]– 0.1% Tween 20) and blocked with Super-
block (PBS containing 4% whey protein, 15% normal goat serum, and
0.5% Tween 20). Breast milk was incubated for 1 h in eight 3-fold serial
dilutions, beginning at 1:5; then the plates were washed two times. For
total IgA detection, 10 l/well of 0.08 g/ml peroxidase-conjugated goat
anti-human IgA (Southern Biotech) was added to the wells. After 1 h of
incubation and four washes, the substrate (SureBlue Reserve Microwell
Substrate; VWR, Radnor, PA) was added, followed by addition of TMB
(3,3=,5,5=-tetramethylbenzidine) Stop Solution (VWR). For SIgA detec-
tion, 10 l/well of mouse anti-human secretory component IgA mono-
clonal antibody (Sigma-Aldrich, St. Louis, MO) at a concentration of 0.87
g/ml was added after the sample incubation. After 1 h of incubation and
two washes, this was followed by incubation with 10 l/well of a 1:4,000
dilution of horseradish peroxidase-conjugated goat anti-mouse IgG
(Southern Biotech). After 1 h of incubation and four washes, the substrate
and then the stop solution were added. Absorbance of the wells was read at
450 nm immediately after addition of the stop solution.
Statistical methods. Logistic regression was used to calculate the as-
sociation between plasma and breast milk HIV-1 Env-specific IgG and
IgA with the outcome of postnatal HIV-1 transmission or nontransmis-
sion. Separate models were run for each antigen, and a false discovery rate
(FDR) (33) was used to account for multiple comparisons within a spe-
cific set of plasma or breast milk samples by isotype. Logistic regression
was also applied to the assessments of ADCC activity and TZM-bl HIV-1
neutralization. No adjustments to the alpha level were made for these
comparisons. All logistic models controlled for CD4 T cell count, which
was also used for matching, and plasma viral load at an alpha level of 0.05.
Wilcoxon two-sample tests (also known as Mann-Whitney U tests)
were performed at the alpha 0.05 level to compare results in uninfected
controls with those in HIV-1-infected transmitters and nontransmitters,
as well as for cohort comparisons. No adjustments to the alpha level were
Pollara et al.
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made for these comparisons. This research is a laboratory substudy using
samples from the control arm of the Malawi-based BAN randomized
clinical trial with a fixed number of transmitters (n  22). Thus, the
number of available transmitter samples limited the size of the cohort, and
the research study was not powered to a specific outcome based on an
assumed difference between transmitters and nontransmitters.
RESULTS
Breast milk neutralization responses are not associated with
postnatal HIV-1 transmission risk. To investigate if maternal
neutralization responses were associated with postnatal transmis-
sion in our study cohort, we assessed the HIV-1 neutralization
activity of breast milk from transmitting and nontransmitting
mothers using the TZM-bl HIV-1 neutralization assay. Milk from
HIV-1-uninfected women was included to define the low, innate
background levels of neutralization commonly observed with
breast milk and other mucosal samples (8, 34, 35). We found that
the milk from transmitting and nontransmitting women had
higher neutralization activities against the tier 1 clade-matched
isolate C.MW965 than those observed in uninfected control
women (Fig. 1A). However, we found no significant difference in
the frequencies of milk samples with detectable neutralization re-
sponses among transmitting and nontransmitting women (95.5%
and 86.2%, respectively; P  0.441, Fisher’s exact test). Moreover,
the milk neutralization potency (measured as the 50% inhibitory
dose [ID50]) against C.MW965 was not associated with transmis-
sion risk (odds ratio [OR], 1.40; P  0.661) (see Table S1 in the
supplemental material). We also measured neutralization potency
of available plasma samples from 10 transmitting and 32 non-
transmitting mothers collected in parallel with milk samples to
determine if the maternal peripheral neutralizing antibody re-
sponse was associated with postnatal transmission. The plasma
neutralization ID50 titers against the tier 1 isolate C.MW965 were
similar among transmitters and nontransmitters and did not in-
dicate any association with transmission status (OR  4.05, P 
0.210).
We next evaluated the neutralization potency of breast milk
against a non-clade-matched tier 1 HIV-1 isolate, B.MN, and a
clade-matched tier 2 transmitted founder virus isolated from
a postnatally infected Malawian infant, C.1209BMH5 (Fig.
1B and C) (23). The ID50 neutralization titers against these
isolates did not significantly differ between HIV-infected
nontransmitting women and uninfected controls (B.MN, P  0.201;
C.1209BMH5, P  0.092; Wilcoxon test).
Breast milk ADCC activity is not associated with postnatal
transmission risk. ADCC activities of breast milk of transmitting
and nontransmitting women were first assessed against target cells
coated with recombinant gp120 representing the clade C Mala-
wian breast milk-transmitted virus 4403BMC5 using the ADCC-
GTL assay (23, 24). Milk of the HIV-1-infected transmitting and
nontransmitting women displayed specific ADCC activity which
was significantly higher (P  0.001, Wilcoxon test) than that of
noninfected control mothers (Fig. 2A and B). However, neither
the milk ADCC potency (OR  1.00, P  0.891) nor milk ADCC
Ab titers (OR  0.82, P  0.638) were associated with reduced risk
of postnatal HIV-1 transmission (see Table S1 in the supplemental
material). Concordant results were obtained in assays conducted
with available maternal plasma samples (potency, OR  1.01 and
P  0.902; titer, OR  2.57 and P  0.591).
To further characterize the ADCC response of transmitting
and nontransmitting women, we next evaluated the milk ADCC
activity directed against target cells infected with HIV-1
4403BMC5 IMC virus (27) using the ADCC-Luc assay (Fig. 2C
and D). HIV-1-infected target cells express the diversity of native
forms of cell surface HIV-1 Env and likely better mimic the type of
target cells present in vivo (36). However, neither breast milk
ADCC potency (OR  1.05, P  0.133) nor ADCC Ab titers
(OR  1.82, P  0.269) against HIV-infected target cells were
associated with risk of postnatal transmission of HIV-1 (see Table
S1 in the supplemental material).
Breast milk Env-binding IgG responses are not associated
with postnatal transmission risk. In the absence of identifying
functional antibody responses associated with reduced risk of
postnatal HIV-1 transmission, we next evaluated the magnitude
and specificities of HIV-1 Env-binding antibodies present in
breast milk of transmitting and nontransmitting mothers. We
measured the magnitude of breast milk IgG binding to a multi-
FIG 1 Magnitude of breast milk neutralization in uninfected and postnatal
transmitting and nontransmitting mothers. The breast milk neutralization
50% inhibitory dose (ID50) was measured by TZM-bl pseudovirus assay
against tier 1 C.MW965 (A), tier 1 B.MN.3 (B), and tier 2 C.1209BMH5 (C).
Samples from nine uninfected controls were included to represent nonspecific
background activity. Tier 1 C.MW965 neutralization responses among trans-
mitting and nontransmitting women were significantly above background lev-
els observed in uninfected control women (Wilcoxon test). Each dot repre-
sents milk from one donor, and medians are indicated with black horizontal
lines.
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clade panel of Env antigens that included epitope regions found to
correlate with reduced infection risk in the RV144 clinical trial
(clade B and C V1/V2 and clade C V3 [14–19]). The panel also
included a clade C Env gp140 (1086C) (32), clade C breast milk-
transmitted founder gp120s (4403 BMC5 and 1209 BMH5) (23),
consensus gp120 (Con6), consensus gp140 protein (ConS), and
B.MN gp41. Using logistic regression modeling, we found that the
magnitudes of total milk IgG binding to the interrogated Env an-
tigens were not associated with postnatal HIV-1 transmission risk
(see Table S2 in the supplemental material). The magnitude of
maternal plasma IgG Env-binding responses also did not associate
with postnatal transmission risk (see Table S3 in the supplemental
material).
Breast milk Env-specific IgA responses and postnatal trans-
mission risk. We next assessed the magnitude of the Env-binding
IgA response against a multiclade panel of HIV-1 Env antigens,
including gp140 and gp120 Env proteins, as well as gp41, V3, C1,
and V1V2 Env antigens.
We found no significant difference in the magnitude of total
milk IgA (Table 2) or plasma IgA (see Table S4 in the supplemen-
tal material) binding to any of the interrogated Env antigens be-
tween transmitting and nontransmitting women in the logistic
regression model. Although the antibody binding magnitudes
were not significantly different after correction for multiple com-
parisons, the magnitude of breast milk total IgA binding to con-
sensus gp140 antigens A1.con env03 and B.con env03 gp140 indi-
cated a trend toward association with reduced transmission
FIG 2 Antibody-dependent cell-mediated cytotoxicity (ADCC) activity and ADCC antibody (Ab) titer against gp120-coated and HIV-1-infected target cells in
breast milk from uninfected and postnatal transmitting and nontransmitting mothers. (A and B) Maximum observed ADCC activity measured as percent
granzyme B (GzB)-positive target cells (A), and ADCC Ab titers of breast milk samples against 4403BMC5 gp120-coated target cells in the ADCC GranToxiLux
(ADCC-GTL) assay (B). (C and D) Breast milk maximum percent specific ADCC killing activity (C), and ADCC Ab titers against 4403BMC5 HIV-1-infected
target cells in the ADCC-Luc assay (D). Samples from nine uninfected controls were included to represent nonspecific background activity and were tested in two
independent experiments, for a total n  18 in the ADCC-Luc assay. Maximum ADCC activities and Ab titers among transmitting and nontransmitting women
were above background levels observed in uninfected control subjects as indicated (Wilcoxon test). Each point represents an individual donor, except in panels
C and D, where duplicate testing of the uninfected controls is included, and all 18 data points are shown. Medians are indicated with black horizontal lines.
TABLE 2 Odds ratios for the association between breast milk IgA
binding to HIV-1 antigens by BAMA and HIV-1 transmission to the
infant via breast milk in the BAN Study, Malawi
Antigena
Logistic regression model for transmitters
OR (95% CI)b P valuec FDRd
A1.con env03 gp140 0.40 (0.17–0.93) 0.034 0.240
A244 gD- gp120 0.82 (0.52–1.32) 0.419 0.488
B.con env03 gp140 0.57 (0.38–0.86) 0.007 0.101
V3.C 1.17 (0.72–1.88) 0.530 0.571
Bio-C1_104.BC 0.76 (0.47–1.21) 0.242 0.408
4403 BMC5 gp120 0.80 (0.53–1.21) 0.292 0.408
C1 0.67 (0.42–1.08) 0.098 0.314
Con6 gp120/B 0.75 (0.52–1.09) 0.135 0.314
ConS gp140 0.74 (0.51–1.09) 0.129 0.314
MN gp41 0.73 (0.50–1.06) 0.096 0.314
gp70 B.CaseA2_V1V2/169K 1.24 (0.77–2.00) 0.381 0.485
gp70 B.CaseA_V1V2 1.32 (0.81–2.15) 0.269 0.408
gp70 C.1086C_V1V2 1.02 (0.64–1.64) 0.932 0.932
1086C gp140 0.78 (0.55–1.11) 0.163 0.326
a Detailed descriptions of antigens can be found in Materials and Methods.
b Odds ratios (ORs) and 95% confidence intervals (CI) for binding antibody multiplex
assay (BAMA) mean fluorescence intensities were determined by logistic regression
modeling controlling for log10 plasma viral load and peripheral CD4
 T cell count.
Significant odds ratios less than 1 indicate that nontransmitters have higher responses
than transmitters.
c Immune variables with unadjusted P values of 0.05 are in boldface.
d FDR, false discovery rate.
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(A1.con env03 gp140, P  0.034 and FDR  0.240; B.con env03
gp140, P  0.007 and FDR  0.101) (Table 2). These observations
prompted additional exploration into the potential role of breast
milk IgA in protection against postnatal HIV-1 transmission.
We first compared the magnitude of breast milk IgA binding to
A1.con and B.con env03 gp140s of transmitting and nontransmit-
ting women to uninfected women. Interestingly, the magnitudes
of IgA binding responses to the A1.con env03 and B.con env03
gp140 antigens in breast milk of transmitting women were similar
to those of 30 uninfected women, yet milk of nontransmitting
women bound with significantly higher magnitude than milk of
uninfected women (A1.con env03 gp140, P  0.018; B.con env03
gp140, P  0.001) (Fig. 3A and B). These observations support the
trend observed in the logistic regression model and suggest that
the breast milk IgA responses of nontransmitting mothers are dif-
ferent from those of transmitting mothers.
Breast milk IgA binding to B.con env03 gp140 is associated
with reduced postnatal HIV-1 transmission risk. To further
probe these differences, we performed exploratory analysis to de-
termine if breast milk IgA binding responses directed against the
A1.con and B.con env03 gp140 antigens were associated with re-
duced risk of transmission. For these exploratory analyses, no ad-
justments for multiple comparisons were made to the P values of
the logistic regression models. We used a standard single-antigen
plate-based ELISA to confirm that the binding of total breast milk
IgA to the antigen that most closely associated with transmission
risk in the primary analysis, B.con env03 gp140, was in fact asso-
ciated with postnatal mother-to-child transmission risk. The
magnitudes of the Env-specific IgA binding responses (measured
as log10 area under the curve [AUC] above positivity threshold) of
both transmitting and nontransmitting women measured by
ELISA were significantly higher than those observed in uninfected
controls (Fig. 3C). Moreover, this response was associated with
transmission risk in the exploratory analysis using logistic regres-
sion modeling (OR  0.51, P  0.020) (Table 3). Thus, the mag-
nitude of breast milk IgA binding to B.con env03 gp140 is a pos-
sible correlate of postnatal HIV-1 transmission risk in this study
cohort.
Breast milk SIgA binding to B.con env03 gp140 is associated
with reduced postnatal transmission risk. We next used SIgA
BAMA to assess the relationship between the magnitude of breast
milk SIgA binding to consensus Env gp140 antigens and postnatal
transmission risk. The magnitudes of SIgA binding to consensus
A, B, and C gp140s were significantly higher among transmitting
and nontransmitting women than among uninfected controls (see
Fig. S1A to C in the supplemental material). Moreover, using ex-
ploratory logistic regression analysis (no adjustment of P value for
multiple comparisons), the magnitude of breast milk SIgA bind-
ing to B.con env03 gp140 was significantly associated with post-
natal transmission risk (OR  0.54, P  0.032) (Table 3), concor-
dant with the results obtained for total IgA binding with this
antigen.
To confirm the association between the magnitude of the Env-
specific SIgA response and transmission risk, we also utilized a
standard single-antigen ELISA to determine the relationship
between breast milk SIgA binding to B.con env03 gp140 and
postnatal transmission risk (see Fig. S1D in the supplemental
material). While the SIgA responses in transmitting and nontrans-
mitting women measured by ELISA were not significantly associ-
ated with postnatal transmission risk in the multivariate logistic
regression model, the point estimate was in the direction of higher
responses among nontransmitting women and reduced risk of
HIV-1 transmission (OR  0.51, P  0.053) (Table 3).
No significant interactions between breast milk Env-binding
IgA and ADCC responses associated with postnatal transmis-
sion risk. In the secondary post hoc analysis of the immune corre-
lates of infection risk in the RV144 clinical trial, it was reported
that ADCC activity was associated with reduced infection risk in
vaccine recipients with low levels of Env-specific plasma IgA (15).
Accordingly, we probed for similar interactions within our study
cohort. Logistic models with breast milk IgA binding to A1.con
env03 gp140 and B.con env03 gp140 were assessed for interaction
FIG 3 Breast milk total IgA binding to select HIV-1 envelope (Env) antigens
in uninfected and postnatal transmitting and nontransmitting mothers. The
magnitude of the milk IgA binding responses measured by binding antibody
multiplex assay (BAMA) against A1.con env03 gp140 (A) and B.con env03
gp140 (B) in transmitting women were similar to responses of 30 uninfected
women, whereas the nontransmitting women had significantly higher IgA re-
sponses against these Env antigens than uninfected women, as indicated (Wil-
coxon test). Binding magnitude is reported as mean fluorescent intensity
(MFI). (C) Breast milk total IgA binding to B.con env03 gp140 measured by
enzyme-linked immunosorbent assay (ELISA). The magnitude of binding,
measured as the area under the curve among transmitting and nontransmit-
ting women, was significantly above background levels observed in uninfected
control subjects (Wilcoxon test) when measured by ELISA. Each dot repre-
sents milk from one donor, and medians are indicated with black horizontal
lines.
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with ADCC potency and ADCC titers as determined for both
HIV-1 Env gp120-coated target cells and HIV-1-infected target
cells. These two antigens were selected for the interaction analysis
because the IgA responses to these antigens were most strongly
associated with reduced risk of postnatal HIV-1 transmission in
our cohort. However, no significant interactions between breast
milk ADCC responses and milk IgA binding levels to these Env
gp140 antigens were identified (see Table S5 in the supplemental
material).
DISCUSSION
In this study, we compared the HIV-1 Env-specific breast milk
and plasma antibody responses of clade C HIV-1-infected postna-
tal transmitting and nontransmitting mothers in the control arm
of the Malawian BAN randomized clinical trial. This study pro-
vided a unique opportunity to investigate humoral correlates of
reduced postnatal mother-to-child transmission risk in the ab-
sence of postnatal antiretroviral therapy (20). Although no statis-
tically significant associations were identified in the primary logis-
tic regression models after correction for multiple comparisons, in
subsequent exploratory analysis, the breast milk IgA responses
against B.con env03 gp140 Env were associated with reduced
HIV-1 postnatal transmission risk by two independent but related
measures: total IgA binding by single-antigen ELISA and SIgA
binding by BAMA. In addition, the SIgA ELISA data suggested an
association with reduced risk of transmission (P  0.053), further
supporting the potential role of breast milk consensus gp140-spe-
cific IgA responses in protection against HIV-1 postnatal trans-
mission.
In the RV144 trial, high levels of Env-specific plasma IgA re-
sponses directly correlated with HIV-1 infection risk, generating
the hypothesis that plasma IgA may interfere with beneficial IgG-
mediated antibody responses such as ADCC activity (15, 37). Un-
fortunately, no mucosal samples were collected during the RV144
clinical trial, and infant plasma samples were not included from
the BAN study cohort, thereby impeding direct comparisons re-
garding the role of plasma and mucosal IgA in risk of infection/
transmission across these two studies. However, these two oppos-
ing risk correlates for circulating plasma IgA and breast milk total
and SIgA suggest that systemic and mucosal IgA may play differ-
ential roles in protection from HIV-1 infection, likely depending
on the site and mode of infection and on the characteristics of the
IgA responses, including fine specificity. In the RV144 trial, some
vaccine-induced IgA antibodies and potent ADCC-mediating IgG
antibodies competed for binding to conformational epitopes
within the first constant (C1) region of Env (15, 38). The epitope
specificities of the mucosal IgA antibodies correlating with re-
duced transmission risk in our study have not yet been identified.
However, we found no interaction between the magnitude of IgA
binding responses and breast milk ADCC activity, suggesting that
the mucosal IgA response in nontransmitting mothers targets
epitopes that do not interfere with potentially beneficial IgG re-
sponses. Moreover, we observed no association of breast milk and
plasma IgA or IgG binding to V1/V2 or V3 with postnatal trans-
mission risk, suggesting that potentially protective mucosal IgA
responses of nontransmitting mothers target epitopes not previ-
ously identified as potentially protective in the RV144 clinical trial
(14–19).
In our study, neither the neutralization activity nor the ADCC
activity of breast milk or plasma was associated with postnatal
HIV-1 transmission risk. Neutralization responses have inconsis-
tently been associated with reduced prenatal, perinatal, or postna-
tal mother-to-child HIV-1 transmission risk, and prior studies
differ in study design, cohort size, prevalent virus clade, use of
autologous or heterologous HIV-1 virus strains, mode of HIV-1
transmission, and timing of sample collection (39, 40).
A recent study conducted by Mabuka et al. demonstrated
higher Env gp120-specific ADCC activity in milk of nontransmit-
ting women than in that of postnatally transmitting women in a
small (n  19), clade A-infected cohort (11). We did not identify
any association between gp120-specific ADCC activity and risk of
postnatal transmission in our larger (n  87) clade C-infected
cohort. ADCC activity in both studies was measured against target
cells coated with a recombinant gp120 representing a clade-
matched infant-transmitted Env. Our study also assessed ADCC
activity against CD4 T cells infected with clade-matched infant-
transmitted founder virus and found that neither ADCC activity
nor ADCC antibody titer against the HIV-infected targets was
associated with postnatal transmission risk. Importantly, there are
additional differences between the study cohorts beyond size and
prevalent virus clade. In the Mabuka study, milk was collected
from women with high plasma viral load (above the cohort me-
dian), and inclusion was further restricted to only women exhib-
iting robust plasma neutralizing antibody responses (11). In con-
trast, our cohort was restricted only by peripheral CD4 T cell
count (200 cells/l). Plasma viral load, a known transmission
risk factor, was significantly higher among transmitting women in
our cohort, and thus, we controlled for log10 plasma viral load in
our logistic regression model. These differences may account for
the seemingly contradictory study outcomes. It is, however, nota-
ble that in both studies the frequency of breast milk samples with
detectable gp120-specific ADCC activity was high (90%), sug-
gesting that ADCC activity is prevalent in breast milk and may
contribute to the overall low rate of HIV-1 transmission observed
for breastfed infants. A recent study described by Milligan and
colleagues also found no association between maternal plasma
ADCC and infant transmission risk (41). However, their study
also demonstrated that plasma samples collected from infants
born to HIV-1-infected mothers within the first postpartum week
were able to mediate ADCC. Interestingly, infant ADCC levels
TABLE 3 Odds ratios for the association between breast milk total IgA
and secretory IgA binding to consensus HIV-1 gp140 antigens by ELISA
and BAMA with HIV-1 transmission to the infant via breast milk in the
BAN Study, Malawi
Antigenc
Logistic regression model for
transmitters
OR (95% CI)a P valueb
IgA B.con env03 gp140 ELISA AUC 0.51 (0.29–0.90) 0.020
SIgA A1.con env03 gp140 BAMA MFI 0.66 (0.42–1.03) 0.066
SIgA B.con env03 gp140 BAMA MFI 0.54 (0.30–0.95) 0.032
SIgA C.con env03 gp140 BAMA MFI 0.69 (0.41–1.16) 0.161
SIgA B.con env03 gp140 ELISA AUC 0.51 (0.26–1.01) 0.053
a Odds ratios (ORs) and 95% confidence intervals (CI) for were determined by logistic
regression modeling controlling for log10 plasma viral load and peripheral CD4
 T cell
count.
b Immune variables with P values of 0.05 are in boldface.
c ELISA AUC, enzyme-linked immunosorbent assay area under the curve; SIgA,
secretory IgA; BAMA MFI, binding antibody multiplex assay mean fluorescence
intensity.
Pollara et al.
9958 jvi.asm.org October 2015 Volume 89 Number 19Journal of Virology
were associated with reduced risk of infant mortality, suggesting a
role for passively transferred maternal ADCC antibodies in the
control of infant HIV-1 disease progression (41). The degree to
which ADCC and/or virus neutralization contributes to reducing
postnatal transmission rates is likely affected by whether each in-
dividual transmission event involved cell-free or cell-associated
virus, an area of study of paramount importance to better under-
stand the mechanisms of mother-to-child transmission and the
types of antibody responses best suited for protection (42).
The identification of total and secretory IgA binding to a con-
sensus B Env protein as being associated with reduced transmis-
sion risk was unexpected for our clade-C-infected Malawian co-
hort. However, as previously discussed, the epitope specificities of
the breast milk IgA responses have not been mapped in detail, nor
have the sequences of the transmitted virus isolates been deter-
mined for this maternal/infant cohort. It is possible that the B.con
env03 gp140 better matched crucial epitopes of the circulating
clade C viruses prevalent in the cohort than the clade C antigens
included in our binding panel. In addition, it is important to note
that the B.con env03 gp140 is a recombinantly produced mono-
meric protein, not a native envelope trimer. It is conceivable that
certain monomeric envelope proteins may more accurately repre-
sent particular structural aspects of the native envelope than oth-
ers, regardless of envelope clade. The identification of a mucosal
Env-specific IgA response as a potential correlate of reduced
transmission risk is unexpected as our group (8) and others (10,
11) have demonstrated that the Env-specific IgG responses are of
higher magnitude than those of IgA in breast milk and are respon-
sible for the majority of breast milk virus neutralization and
ADCC. Yet mucosal IgA may function through alternative antivi-
ral mechanisms, such as virus aggregation, mucus binding, or in-
hibition of epithelial cell transcytosis (43, 44). Interestingly, mu-
cosal Env-specific IgA responses have also been observed among
highly exposed seronegative individuals, including female sex
workers and discordant couples (45). In contrast, previous studies
have not found breast milk Env-specific IgA to be associated with
reduced risk of postnatal HIV-1 transmission (9, 11–13). A signif-
icant difference between our study and previous breast milk
studies is that we assessed the magnitude of Env-binding IgA
responses, not frequency of responders, as correlates of trans-
mission risk. Moreover, we used the highly sensitive technique of
BAMA, which may be able to better discriminate low-level IgA
responses than the techniques previously employed.
Importantly, the results of this study suggest a protective role
for mucosal HIV-1 Env-specific IgA in the context of postnatal
mother-to-child transmission. We have recently demonstrated
that combined systemic and mucosal vaccination strategies can
induce robust Env-specific IgA responses in the breast milk of
lactating rhesus monkeys (30). Thus, our results support further
investigations to gain a better understanding of the antiviral func-
tions of mucosal IgA and the potential mechanisms by which it
reduces the risk of HIV-1 transmission via breastfeeding. More-
over, methods to enhance milk Env-specific IgA responses should
be further developed and tested in preclinical nonhuman primate
models as a potential strategy to increase the safety of breastfeed-
ing for all infants in areas of HIV-1 prevalence.
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